

Document and Entity Information	3 Months Ended	
	Dec. 31, 2012	Feb. 11, 2013
Document and Entity Information [Abstract]		
Entity Registrant Name	MEDICAL INTERNATIONAL TECHNOLOGY INC	
Entity Central Index Key	000112372	
Amendment Flag	false	
Current Fiscal Year End Date	--09-30	
Document Type	10-Q	
Document Period End Date	Dec. 31, 2012	
Document Fiscal Year Focus	2013	
Document Fiscal Period Focus	Q1	
Entity Filer Category	Smaller Reporting Company	
Entity Common Stock, Shares Outstanding	83,804,627	

Consolidated Balance Sheet(USD (\$))	Dec. 31, 2012	Sep. 30, 2012
Current Assets		
Cash and cash equivalents	\$ 79,399	\$ 303,497
Accounts receivable	13,870	56,067
Inventories	341,576	316,440
Prepaid expenses	9,980	20,203
Total Current Assets	444,825	696,207
Long Term Investment		
Investment in MIT China Joint Venture	65,472	146,343
Property and Equipment		
Tooling and machinery	705,704	713,779
Furniture and office equipment	143,137	144,775
Leasehold improvements	29,448	29,785
Total property and equipment	878,289	888,339
Less accumulated depreciation	(635,472)	(612,592)
Total property and equipment, net	242,817	275,747
Other Assets		
Patents (net of accumulated amortization of \$3,392 and \$13,516)	41,973	44,857
Total assets	795,087	1,163,154
Current Liabilities		
Bank line		101,660
Deferred income	1,405,663	1,385,906
Accounts payable and accrued expenses	147,765	160,174
Amounts due to related parties		152,723
Current portion of long term debts	51,442	23,736
Total current liabilities	1,604,870	1,671,476
Long-Term Debts	133,814	176,242
Total Liabilities	1,738,684	1,847,718
Stockholders' Equity (Deficit)		
Preferred stock, \$.0001 par value; 3,000,000 shares authorized; No issued and outstanding shares.		
Common stock, \$.0001 par value; 100,000,000 shares authorized; 83,804,627 and 79,090,627 issued and outstanding, respectively	7,979	7,979
Additional paid-in capital	12,867,476	12,867,476
Deficit	(13,428,313)	(13,172,164)
Other comprehensive income (loss)	(390,738)	(387,855)
Total Stockholders' Equity (Deficit)	(943,596)	(684,564)
Total Liabilities and Stockholders' Equity (Deficit)	\$ 795,088	\$ 1,163,154

Consolidated Balance Sheet (Parenthetical) (USD \$)	Dec. 31, 2012	Sep. 30, 2012
Balance Sheet [Abstract]		
Accumulated amortization (Patents)	\$ 3,392	\$ 13,516
Preferred stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued		
Preferred stock, shares outstanding		
Common stock, par value	\$ 0.0001	\$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	83,804,627	79,090,627
Common stock, shares outstanding	83,804,627	79,090,627

Consolidated Statements of Operations (Unaudited) (USD \$)	3 Months Ended	
	Dec. 31, 2012	Dec. 31, 2011
Statements Of Operations [Abstract]		
Sales	\$ 113,621	\$ 74,836
Cost of sales	(51,921)	(40,434)
Gross profit (loss)	61,700	34,402
Operating expenses		
Selling, general, and administrative expenses	(233,879)	(175,836)
Total operating expenses	(233,879)	(175,836)
Other Income (Expense) Equity earnings (loss) on MIT China Joint Venture	(80,870)	(90,794)
Interest	228	178
Interest expense	(3,328)	(3,103)
Other income (expense), net	(63,971)	(93,719)
Net loss	\$ (256,149)	\$ (235,153)
Net loss per common share	\$ (0.003)	\$ (0.003)
Weighted average common shares outstanding - basic and diluted	83,804,627	79,270,627

Consolidated Statements of Cash Flows (USD \$)	3 Months Ended	
	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:		
Net loss	\$ (256,149)	\$ (235,153)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Equity loss from MIT China Joint Venture	80,870	90,794
Depreciation and amortization expense	33,201	19,742
Common stock issued for services		
Related party payables settle by common stock		
Capitalization of related party debts		
Changes in:		
Accounts receivable	42,196	13,352
Inventories	(25,137)	19,770
Prepaid expenses	10,223	5,422
Accounts payable and accrued liabilities	(12,408)	40,319
Deferred income	19,757	65,237
Net cash used by operating activities	(107,446)	19,483
Cash flows from investing activities:		
Acquisition of patents	(1,015)	(13,505)
Investment in MIT China joint venture		
Tooling and machinery		(48,058)
Net cash used by investing activities	(1,015)	(61,563)
Cash flows from financing activities:		
Bank line	(101,660)	31,167
Bank loans	(14,722)	57,477
Proceeds from issuance of stock, net		18,000
Increase in amounts due to related parties		(3,892)
Issuance of notes payable		
Repayment on notes payable		
Net cash provided from financing activities	(116,382)	40,418
Effect of exchange rates	745	4,983
Increase (decrease) in cash	(224,096)	3,321
Cash, beginning of period	303,497	10,889
Cash, end of period	79,399	14,210
Supplemental disclosure of cash flow information:		
Cash paid for interest	3,328	3,103
Cash paid for federal income taxes		
Supplemental disclosure of non-cash transactions		
Common stock issued for debt reductions		

Consolidated Statements of Comprehensive Loss (USD \$)	3 Months Ended	
	Dec. 31, 2012	Dec. 31, 2011
Statements Of Comprehensive Loss [Abstract]		
Net loss	\$ (256,149)	\$ (235,153)
Other comprehensive income (loss)		
Foreign currency translation adjustment	(2,884)	(13,441)
Net comprehensive income (loss)	\$ (259,033)	\$ (248,594)

Consolidated Statement of Stockholders' (Deficit) (USD \$)	Total	Common Stock	Additional Paid-In Capital	Deficit
Beginning Balance at Sep. 30, 2012	\$ (684,564)	\$ 7,979	\$ 12,867,386	\$ (13,172,164)
Beginning Balance, Shares at Sep. 30, 2012		83,804,627		
Shares issued for debts				
Shares issued for debts, Shares				
Shares issued for services				
Shares issued for services, Shares				
Shares issued for additional capital				
Shares issued for additional capital, Shares				
Net loss	(256,149)			(256,149)
Ending Balance at Dec. 31, 2012	\$ (943,596)	\$ 7,979	\$ 12,867,386	\$ (13,428,313)
Ending Balance, Shares at Dec. 31, 2012		83,894,627		

Basis of Presentation	3 Months Ended Dec. 31, 2012
Basis Of Presentation [Abstract]	
Basis of Presentation	Note 1 – Basis of Presentation
	Interim Financial Statements
	The accompanying unaudited condensed consolidated financial statements of Medical International Technology, Inc. ("MIT" or the "Company") and its subsidiary (collectively referred to as the "Company") have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. All significant intercompany balances and transactions have been eliminated. These financial statements do not include all information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. It is recommended that these interim unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2012.
	In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months period ended December 31, 2012 are not necessarily indicative of the results which may be expected for any other interim periods or for the year ending September 30, 2013. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Inventories	3 Months Ended Dec. 31, 2012															
Inventories [Abstract]																
Inventories	Note 2 – Inventories															
	Inventories at December 31, 2012 and September 30, 2012 consist of the following:															
	<table border="1"> <thead> <tr> <th></th> <th style="text-align: right;">December 31, 2012</th> <th style="text-align: right;">September 30, 2012</th> </tr> </thead> <tbody> <tr> <td>Raw materials</td> <td style="text-align: right;">\$ 201,586</td> <td style="text-align: right;">\$ 242,528</td> </tr> <tr> <td>Work in process</td> <td style="text-align: right;">88,796</td> <td style="text-align: right;">63,255</td> </tr> <tr> <td>Finished goods</td> <td style="text-align: right;">12,755</td> <td style="text-align: right;">10,657</td> </tr> <tr> <td>Total</td> <td style="text-align: right;">\$ 303,137</td> <td style="text-align: right;">\$ 316,440</td> </tr> </tbody> </table>		December 31, 2012	September 30, 2012	Raw materials	\$ 201,586	\$ 242,528	Work in process	88,796	63,255	Finished goods	12,755	10,657	Total	\$ 303,137	\$ 316,440
	December 31, 2012	September 30, 2012														
Raw materials	\$ 201,586	\$ 242,528														
Work in process	88,796	63,255														
Finished goods	12,755	10,657														
Total	\$ 303,137	\$ 316,440														

Property and Equipment	3 Months Ended Dec. 31, 2012
Property and Equipment [Abstract]	
Property and Equipment	Note 3 – Property and Equipment
	The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the three months ended December 31, 2012 and 2011 was \$17,488 and \$19,742, respectively.

Intangible Assets	3 Months Ended Dec. 31, 2012										
Intangible Assets [Abstract]											
Intangible Assets	Note 4 – Intangible Assets										
	As of December 31, 2012, the Company has net patents on certain technologies aggregating \$41,973. Amortization expense for the years ended December 31, 2012 and 2011 were \$2,254 and \$2,254, respectively. During the three months ended December 31, 2012, the Company capitalized patent costs on its needle-free injector of \$1,015. Following is a detail of patents at December 31, 2012.										
	<table border="1"> <thead> <tr> <th></th> <th style="text-align: right;">Gross Intangible Assets</th> <th style="text-align: right;">Accumulated Amortization</th> <th style="text-align: right;">Net Intangible Assets</th> <th style="text-align: right;">Weighted Average Life (Years)</th> </tr> </thead> <tbody> <tr> <td>Patents</td> <td style="text-align: right;">\$ 67,835</td> <td style="text-align: right;">\$ 25,862</td> <td style="text-align: right;">\$ 41,973</td> <td style="text-align: right;">7.5 through 15</td> </tr> </tbody> </table>		Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)	Patents	\$ 67,835	\$ 25,862	\$ 41,973	7.5 through 15
	Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)							
Patents	\$ 67,835	\$ 25,862	\$ 41,973	7.5 through 15							

Joint Venture Agreement	3 Months Ended Dec. 31, 2012
Joint Venture Agreement [Abstract]	
Joint Venture Agreement	Note 5 – Joint venture agreement
	<p>On May 6, 2009, the Company entered into a certain joint venture agreement (the "Joint Venture Agreement") with Jiangsu Hualan Biotechnology Ltd. (China) ("Jiangsu Hualan"). Pursuant to the Joint Venture Agreement, the parties thereto established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. ("MIT China" or the "Joint Venture"), focusing on research, production and sales of medical equipments, import and export of medical equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall amount to \$2,000,000, and the registered capital shall amount to \$1,400,000. The Company invested cash of \$426,678 and transferred the license rights to produce and sell the Company's needle-free injectors products into the Joint Venture. The license rights were valued at \$280,000 under the agreement. The contributions by the Company resulted in the Company owning 49% of the registered capital of the Joint Venture. Jiangsu Hualan contributed cash of \$714,000, and owns 51% of the registered capital.</p> <p>Under the Joint Venture Agreement, the Company appointed 1 member, and Jiangsu Hualan appointed 2 members, to the board of directors of the Joint Venture. Profits of the Joint Venture will be allocated based upon each party's investment in the registered capital.</p> <p>During the period from May 6, 2009 to September 30, 2009, the Joint Venture had not commenced operations. The Joint Venture commenced operations during the Company's 1st quarter of fiscal 2010.</p> <p>During the third quarter of fiscal year 2011, MIT China purchased 151,000 sq. ft. of land and began construction of its first building in Taizhou (China Medical City). This first building of 40,000 sq. ft. will be used for the production of injectors for the Chinese market. The first stage (the offices) was completed and employees were moved into the facility in August 2012. The second part of the construction is scheduled to be complete during the first quarter of 2013, which will contain the production facility capable of supplying a large number of injectors and disposables to the Chinese market.</p> <p>In March 2012, MIT China agreed and sold 9% of the joint venture for an investment of 18,000,000 RMB (US\$3,000,000). Jiangsu Hualan now has 46.41%, the Company has 44.59%, and Taizhou Amazon Investment Center has 9% ownership in the MIT China joint venture.</p> <p>The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, "Investment — Equity Method and Joint Venture" (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, "The Equity Method of Accounting for Investments in Common Stock." Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of September 30, 2012, the Company's recorded investment in the MIT China was \$146,343. During the three months ended December 31, 2012, the Company recorded an equity loss from its investment in MIT China of \$80,870.</p>

Bank Line	3 Months Ended Dec. 31, 2012
Bank Line [Abstract]	
Bank Line	Note 6 – Bank Line
	The Company has an equipment line of credit up to a maximum of \$350,000. The line is secured by account receivables, inventories, equipment and all other assets of the Company. At December 31, 2012, the Company had no amounts outstanding under the agreement.

Related Party Transactions	3 Months Ended Dec. 31, 2012
Related Party Transactions [Abstract]	
Related Party Transactions	Note 7 – Related Party Transactions
	There are not related party balances at December 31, 2012 and September 30, 2012.

Stockholders' Equity (Deficit)	3 Months Ended Dec. 31, 2012
--------------------------------	---------------------------------

Stockholders' Equity (Deficit)
[Abstract]
 Stockholders' Equity (Deficit)

Note 8 – Stockholders' Equity (Deficit)

Issuance of Common Stock

From time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings.

For the quarter ended December 31, 2012, there was no common stock issuance.

For the quarter ended December 31, 2011, the Company issued an aggregate of 180,000 shares of its common stock for cash under private placement transactions for total proceeds of \$17,980.

Preferred Stock

As of December 31, 2012, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval

Outstanding Options

As of December 31, 2012 and 2011, there are no options outstanding to purchase shares of the Company's common stock.

Outstanding Warrants

During the period ended June 30, 2011, the Company issued warrants to purchase an aggregate of 2,815,000 common shares at an exercise price of \$0.15 per share and 333,332 common shares at an exercise price of \$0.20 per share. The warrants were issued in connection with private placements completed during 2011. The warrants vested immediately and have terms of one to two years that expire between March 28, 2012 and February 4 2013. As at September 30, 2012, 333,332 common shares at an exercise price of \$0.20 per share where no exercised and they expired in March 2012. The total as at September 30 2012 issued warrants to purchase an aggregate of 2,481,668 common shares at an exercise price of \$0.15. The Company estimated the fair value of the warrants using the Black-Scholes method with assumptions including: (1) term of 1 year to two years; (2) a computed volatility rate of 205%; (3) a discount rate of \$0.45%; and (4) zero dividends. The fair value of the warrants was estimated to be \$218,991.

Operating Leases

3 Months Ended

Dec. 31, 2012

Operating Leases [Abstract]

Operating Leases

Note 9 – Operating Leases

The Company leases its office and warehouse space under an operating lease that expires on December 31, 2014 that calls for a monthly rent of \$4,414. Rent expense for the year ended December 31, 2012 was approximately \$12,712.

Future minimum lease commitments pertaining to the lease expire as follow:

Year ended

September 30, 2013	38,136
September 30, 2014	50,848
Thereafter	12,712
	<u>\$ 101,696</u>

Deferred Income

3 Months Ended

Dec. 31, 2012

Deferred Income [Abstract]

Deferred Income

Note 10 – Deferred Income

Deferred income consists of the following at December 31, 2012 and September 30, 2012:

	December 31, 2012	September 30, 2012
Deposits from customers and distributors	\$ 333,163	\$ 313,406
Non-refundable Distribution Rights Deposit	1,072,500	1,072,500
Total	<u>\$ 1,405,663</u>	<u>\$ 1,385,906</u>

On November 1, 2007, the Company received a deposit of \$1,300,000 for the worldwide rights to market and sells while maintaining MIT CANADA right to sell all Medical International Technology Inc.'s Needle-Free Jet-Injectors for the human and animal markets. This deposit was part of an agreement under negotiation, which was finalized in January 2009. Upon finalization, the Company began recognizing the deposit into income over the contractual life of the agreement. During the year ended September 30, 2010, the Company recognized \$130,000 into income under this agreement. During 2011, the Company was notified of potential litigation related to this contract. Accordingly, due to the uncertainty in a final resolution, the Company ceased recognizing income related to this contract during 2011. Upon a final resolution of the dispute, the Company will begin amortizing the deposit into income over the remaining contractual life of the agreement.

Notes Payable

3 Months Ended

Dec. 31, 2012

Notes Payable [Abstract]

Notes Payable

Note 11 – Notes Payable

Long-term debt consists of the following at December 31, 2012 and September 30, 2012:

	December 31, 2012	September 30, 2012
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.	\$ 114,403	\$ 123,197
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	70,853	76,782
Long-term debt	<u>\$ 185,256</u>	<u>\$ 199,979</u>

Future scheduled principal payments under note agreements are as follows:

Year ended

September 30, 2013	51,442
September 30, 2014	51,442
September 30, 2015	51,442
September 30, 2016	30,930
	<u>\$ 185,256</u>

Contingencies	3 Months Ended Dec. 31, 2012
Contingencies [Abstract] Contingencies	Note 12 – Contingencies Legal Proceedings We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Inventories (Tables)	3 Months Ended Dec. 31, 2012	
Inventories [Abstract] Components of inventory	December 31, 2012	September 30, 2012
Raw materials	\$ 201,586	\$ 242,528
Work in process	88,796	63,255
Finished goods	12,755	10,657
Total	<u>\$ 303,137</u>	<u>\$ 316,440</u>

Intangible Assets (Tables)	3 Months Ended Dec. 31, 2012			
Intangible Assets [Abstract] Summary of patents	Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)
Patents	\$ 67,835	\$ 25,862	\$ 41,973	7.5 through 15

Operating Leases (Tables)		3 Months Ended Dec. 31, 2012	
Operating Leases [Abstract]			
Future minimum lease commitments			
	<u>Year ended</u>		
September 30, 2013	38,136		
September 30, 2014	50,848		
Thereafter	<u>12,712</u>		
	<u>\$101,696</u>		

Deferred Income (Tables)		3 Months Ended Dec. 31, 2012	
Deferred Income [Abstract]			
Components of deferred income			
	December 31, 2012	September 30, 2012	
Deposits from customers and distributors	\$ 333,163	\$ 313,406	
Non-refundable Distribution Rights Deposit	<u>1,072,500</u>	<u>1,072,500</u>	
Total	<u>\$1,405,663</u>	<u>\$1,385,906</u>	

Notes Payable (Tables)		3 Months Ended Dec. 31, 2012	
Notes Payable [Abstract]			
Schedule of long-term debt			
		December 31, 2012	September 30, 2012
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.		\$ 114,403	\$ 123,197
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.		<u>70,853</u>	<u>76,782</u>
Long-term debt		<u>\$ 185,256</u>	<u>\$ 199,979</u>
Future scheduled principal payments of long-term debt	<u>Year ended</u>		
September 30, 2013			51,442
September 30, 2014			51,442
September 30, 2015			51,442
September 30, 2016			<u>30,930</u>
			<u>\$ 185,256</u>

Inventories (Details) (USD \$)	Dec. 31, 2012	Sep. 30, 2012
Components of inventory		
Raw materials	\$ 201,586	\$ 242,528
Work in process	88,796	63,255
Finished goods	12,755	10,657
Total	<u>\$ 341,576</u>	<u>\$ 316,440</u>

Property and Equipment (Details) (USD \$)	3 Months Ended	
	Dec. 31, 2012	Dec. 31, 2011
Property and Equipment (Textual)		
Depreciation expense	\$ 17,488	\$ 19,742
Minimum [Member]		
Property and Equipment (Textual)		
Estimated useful lives of property and equipment	5 years	
Maximum [Member]		
Property and Equipment (Textual)		
Estimated useful lives of property and equipment	7 years	

Intangible Assets (Details) (USD \$)	3 Months Ended		
	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2012
			Dec. 31, 2012
			Minimum [Member]
			Maximum [Member]
			Patents [Member]
Summary of patents			
Gross Intangible Assets			\$ 67,835
Accumulated Amortization	3,392	13,516	25,862
Net Intangible Assets	<u>\$ 41,973</u>	<u>\$ 44,857</u>	<u>\$ 41,973</u>
Weighted Average Life (Years)			7 years 6 months 15 years

Intangible Assets (Details Textual) (USD \$)	3 Months Ended		
	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2012
Intangible Assets (Textual)			
Aggregate net patents	\$ 41,973		\$ 44,857
Amortization expenses	2,254	2,254	
Capitalized patent costs on needle-free injector	\$ 1,015	\$ 13,505	

1 Months Ended

3 Months Ended

1 Months Ended

Joint Venture Agreement (Details)	Mar. 31, 2012 USD (\$)	Mar. 31, 2012 CNY	May 31, 2009 Members	Dec. 31, 2012 USD (\$)	Dec. 31, 2011 USD (\$)	Jun. 30, 2011 sqft	Sep. 30, 2012 USD (\$)	May 06, 2009 USD (\$)	May 31, 2009 Jiangsu Hualan [Member] Members	Mar. 31, 2012 Jiangsu Hualan [Member] [Member]	May 06, 2009 Jiangsu Hualan [Member] USD (\$)	Mar. 31, 2012 Taizhou Amazon Investment Center [Member]
Joint Venture Agreement (Textual)												
Ownership percentage	44.59%	44.59%						49.00%		46.41%	51.00%	9.00%
Cash invested in joint venture	\$ 3,000,000	18,000,000		\$ 65,472			\$ 146,343				\$ 714,000	
Number of members appointed under joint venture agreement			1						2			
Total investment to be made by joint venture								2,000,000				
Registered capital								1,400,000				
Investment in joint venture				146,343				426,678				
Value of license rights								280,000				
Area of land purchase and construction, description						During the third quarter of fiscal year 2011, MIT China purchased 151,000 sq. ft. of land and began construction of its first building in Taizhou (China Medical City). This first building of 40,000 sq. ft. will be used for the production of injectors for the Chinese market. The first stage (the offices) was completed and employees were moved into the facility in August 2012. The second part of the construction is scheduled to be complete during the first quarter of 2013, which will contain the production facility capable of supplying a large number of injectors and disposables to the Chinese market.						
Area of land purchase for construction						151,000						
Area of land use for production of injectors						40,000						
Sale of joint venture percentage for an investment by parent company	9.00%	9.00%										
Equity loss from MIT China Joint Venture					\$ (80,870)	\$ (90,794)						

Bank Line (Details) (USD \$)	Dec. 31, 2012
Bank Line (Textual)	
Maximum equipment line of credit	\$ 350,000
Amount outstanding	

Stockholders' Equity (Deficit) (Details) (USD \$)	3 Months Ended		3 Months Ended		12 Months Ended		3 Months Ended		12 Months Ended		3 Months Ended		12 Months Ended		
	Dec. 31, 2011	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012	Jun. 30, 2011	Sep. 30, 2012	Jun. 30, 2011	Sep. 30, 2012
Stockholders' Equity (Deficit) (Textual)															
Common stock issued		180,000													
Number of common shares to be purchase from Warrants issued												2,815,000	2,481,668	333,332	333,332
Exercise price of warrants												\$ 0.15	\$ 0.15	\$ 0.20	\$ 0.20
Warrants vesting term						1 year	1 year					2 years	2 years		
Warrants, expiration date						Mar. 28, 2012						Feb. 04, 2013			Mar. 31, 2012
Fair value assumptions, expected volatility rate					205.00%										
Fair value assumptions, discount rate					0.45%										
Fair value assumptions, expected dividend payments					\$ 0										
Warrant expense					\$ 218,991										
Preferred stock, shares outstanding															
Options outstanding															
Proceeds from issuance of private placement	\$ 17,980														

Operating Leases (Details) (USD \$)	Dec. 31, 2012
Future minimum lease commitments	
September 30, 2013	\$ 38,136
September 30, 2014	50,848
Thereafter	12,712
Total operating leases	\$ 101,696

Operating Leases (Details Textual) (USD \$)	3 Months Ended Dec. 31, 2012
Operating Leases (Textual)	
Expiry date of operating lease	Dec. 31, 2014
Monthly rent for office and warehouse space	\$ 4,414
Rent expense	\$ 12,712

Deferred Income (Details) (USD \$)	Dec. 31, 2012	Sep. 30, 2012
Components of deferred income		

Deposits from customers and distributors	\$ 333,163	\$ 313,406
Non-refundable Distribution Rights	1,072,500	1,072,500
Deposit		
Total unearned income	<u>\$ 1,405,663</u>	<u>\$ 1,385,906</u>

Deferred Income (Details Textual) (USD \$)	12 Months Ended	
	Sep. 30, 2010	Nov. 01, 2007
Deferred Income (Textual)		
Deposit received for the worldwide rights to market and sell rights		\$ 1,300,000
Deferred revenue recognized	\$ 130,000	

Notes Payable (Details) (USD \$)	Dec. 31, 2012	Sep. 30, 2012
Schedule of long-term debt		
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.	\$ 114,403	\$ 123,197
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	70,853	76,782
Long-term Debt	<u>\$ 185,256</u>	<u>\$ 199,979</u>

Notes Payable (Details 1) (USD \$)	Dec. 31, 2012	Sep. 30, 2012
Future scheduled principal payments of long-term debt		
September 30, 2013	\$ 51,442	
September 30, 2014	51,442	
September 30, 2015	51,442	
September 30, 2016	30,930	
Long-term Debt	<u>\$ 185,256</u>	<u>\$ 199,979</u>

Notes Payable (Details Textual) (USD \$)	3 Months Ended	
	Dec. 31, 2012	
	Installments	
Notes payable to bank [Member]		
Notes Payable (Textual)		
Interest rate in addition to prime rate		3.00%
Number of consecutive installments for repayment of long-term debt		60
Amount of each installment		\$ 2,413.12
Debt maturity date	Jan. 20, 2016	
Canada economic development [Member]		
Notes Payable (Textual)		
Number of consecutive installments for repayment of long-term debt		16
Due date of first installment	Twelve (12) month after the project completion date.	